Navigation Links
Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout
Date:7/9/2008

-- Dr. Fernando Perez-Ruiz Joins Ardea's Inflammatory Disease Scientific

Advisory Board --

SAN DIEGO, July 9 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that it has received regulatory approval to begin a Phase 2a proof-of-concept clinical trial evaluating RDEA806 in gout patients with hyperuricemia. Gout, also known as metabolic arthritis, is a painful and debilitating disease caused by abnormally elevated levels of uric acid in the blood stream, and is the most common form of inflammatory arthritis in men over 40. The Company also announced that gout specialist, Dr. Fernando Perez-Ruiz in Spain, will be the newest member of its inflammatory disease scientific advisory board (SAB).

Ardea previously announced the designation of RDEA594, a major metabolite of RDEA806, the Company's lead human immunodeficiency virus (HIV) development compound, as its lead development candidate for the treatment of patients with gout. RDEA594 does not have antiviral activity, but is believed to be responsible for essentially all of the uric acid lowering effects seen with RDEA806. Uric acid lowering effects have been observed following administration of RDEA806 in Phase 1 and Phase 2 clinical trials that included over 100 subjects.

"The Phase 2a trial should allow us to confirm RDEA594's activity in the target population of patients with gout using its prodrug, RDEA806. Enrollment in the Phase 2a trial should begin shortly and we are on track to initiate a Phase 1 trial with RDEA594 in the second half of this year," said Barry D. Quart, PharmD, Ardea Biosciences' President and CEO. "We also are extremely pleased to add Dr. Fernando Perez-Ruiz to our inflammatory diseases S
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Craig Johnson Joins Ardea Biosciences Board of Directors
2. Ardea Biosciences Presents Inflammation Program Data for Arthritis and Gout at 2008 Annual European Congress of Rheumatology
3. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at Digestive Disease Week 2008
4. Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses
5. Ardea to Present Data on HIV Non-Nucleoside Reverse Transcriptase Inhibitor and Two MEK Inhibitors at Upcoming Medical Conferences
6. Ardea to Present at Cowen and Companys 28th Annual Health Care Conference
7. Ardea Biosciences to Move Headquarters and R&D Laboratories to San Diego
8. Ardea Biosciences Establishes Scientific Advisory Board for Inflammation Program
9. Ardea Biosciences to Present at Roth Capital Partners 20th Annual OC Growth Stock Conference
10. Ardea Biosciences Establishes Scientific Advisory Board for HIV Program
11. Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... a leading North American IT solutions and managed services provider, ... Cisco® Partner Summit Country awards. Cisco named ... of the Year for Canada during ... Montreal . "We are thrilled ... this year,s conference," said David MacDonald , Softchoice,s President ...
(Date:5/1/2015)... , May 1, 2015 Albany Molecular ... William S. Marth , AMRI,s President and Chief ... Merrill Lynch 2015 Health Care Conference on Wednesday, May ... live audio webcast of the presentation can be accessed ... The webcast will be archived for ...
(Date:4/30/2015)... Blythewood, South Carolina (PRWEB) May 01, 2015 ... steam system services, is extremely proud to announce that ... have been named as a winner of a Queen’s ... business success for the design and manufacture of a ... is the revolutionary alternative to traditional steam flow ...
(Date:4/30/2015)... South San Francisco, CA (PRWEB) April 30, 2015 ... revenues for the first quarter of 2015 were $4.4 million, ... The net loss for the first quarter was $8.9 ... compared to a net loss for the same period in ... diluted share. As of March 31, 2015, cash, cash equivalents ...
Breaking Biology Technology:Softchoice recognized with two Country Awards at Cisco Partner Summit 2015 2AMRI to Present at the Bank of America Merrill Lynch 2015 Health Care Conference 2Spirax Sarco Receives a Queen’s Award for Innovation 2Spirax Sarco Receives a Queen’s Award for Innovation 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 6Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 7Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 8
... Therapeutics, Inc. today presented final results from its Phase ... of exenatide) for the treatment of type 2 diabetes ... the Study of Diabetes in Vienna, Austria. Results of ... (FPG) within 24 hours of the start of treatment ...
... BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced ... a conference call and webcast on Wednesday, October 28, at ... , , U.S. / Canada Dial-in Number: ... Participant Code: 51404008, Replay ...
... 30 InteKrin Therapeutics Inc. announced today positive results for ... 45th European Association for the Study of Diabetes ... will be presented at 1:45 PM Friday, October 2, 2009 ... His presentation is entitled "Impact of INT131 Besylate, a Selective ...
Cached Biology Technology:Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference 2Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference 3Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference 4Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference 5BioMarin to Host Third Quarter 2009 Financial Results Conference Call and Webcast on Wednesday, October 28 at 5:00 p.m. ET 2InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting 2
(Date:4/14/2015)... OXFORD, Conn. , April 14, 2015 ... "Company"), a biometric authentication company focused on the growing ... has been nominated for the 2015 New York Design ... The Design100, New York City Design Awards are ... are based on over 2,500 ratings from the marketplace, ...
(Date:4/8/2015)...  Infinisource, a leading provider of SaaS-based Human Capital ... leading supplier of biometric identification and security solutions, ... advanced biometrically-enabled time clock, the companies announced today. ... setting a bold, new standard for the collection ... and mid-size employer. When connected to the iSolved ...
(Date:4/2/2015)... -- Fingerprint Cards (FPC) has received an ... distributor World Peace Industrial Group (WPI), part of WPG ... major part of the shipments will take place during ... manufacturers in China . The order ... revenue guidance of + 1 000 MSEK for 2015.  ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
... with a degree in chemical engineering, was recently elected ... the National Academy of Engineering is among the highest ... honors those who have made outstanding contributions to "engineering ... Space and Missile Systems Center, Air Force Space Command, ...
... Problems related to urination, including incontinence and having to get ... of discussion over recent years. New treatment options have also ... no study has effectively compared the bother of each of ... The FINNO Study is an ongoing questionnaire survey ...
... Ocean to get to the Sargasso Sea to spawn, they swim ... researchers from the University of Southern Denmark report: Even in deep ... is in decline, and all over the world biologists are struggling ... numbers back up. One of the great puzzles is why and ...
Cached Biology News:When you always gotta go… 2Threatened eels disappear in the deep on their way to the Sargasso Sea 2
...
Full-length cDNA 5-PRIME end of clone CS0DE013YM09 of Placenta of Homo sapiens (human). [Source:Uniprot/SPTREMBL;Acc:Q86TS7] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
5(S)-HETE-d8 is used as an internal standard for the quantification of 5(S)-HETE by stable isotope dilution mass spectrometry....
... deuterium atoms at the 9, 10, 12, and ... an internal standard for the quantification of 9(S)-HODE ... by the lipoxygenation of linoleic acid in both ... atherosclerotic plaques, as an esterified component of membrane ...
Biology Products: